Statistics

Total Visits

Views
Early tumour shrinkage (ETS) and depth of response (DpR) with first-line panitumumab (P) plus FOLFOX4 (P-FOLFOX4) or FOLFIRI (P-FOLFIRI) in patients (pts) with wild-type (WT) RAS colorectal cancer (CRC) and liver-limited disease (LLD)64

Select a period of time:

Number of views in the range

Views
Early tumour shrinkage (ETS) and depth of response (DpR) with first-line panitumumab (P) plus FOLFOX4 (P-FOLFOX4) or FOLFIRI (P-FOLFIRI) in patients (pts) with wild-type (WT) RAS colorectal cancer (CRC) and liver-limited disease (LLD)33

Views

Views
January 20252
February 202510
March 202515
April 20253
May 20253
June 20250
July 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore18
United States14
Spain1
 

Top cities views

Views
Alliance1
Council Bluffs1
Los Angeles1
Orlando1